Pacira Biosciences Inc
F:82P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pacira Biosciences Inc
F:82P
|
US |
|
C
|
CenterPoint Energy Inc
XMUN:HOU
|
US |
|
P
|
Pyramid Technoplast Ltd
BSE:543969
|
IN |
Pacira Biosciences Inc
Pacira Biosciences makes non-opioid pain relief products for hospitals, surgery centers, and doctors. Its main product is EXPAREL, a long-acting injectable used to control pain after surgery. It also sells ZILRETTA for knee osteoarthritis pain and iovera, a device that uses cold to block pain nerves for certain procedures. The company makes money mainly by selling these prescription products to healthcare providers and through the pharmacy and hospital supply chain. Doctors use Pacira’s medicines and devices when they want to reduce opioid use, manage pain for a longer period, or improve recovery after surgery or joint treatment. Pacira stands out because it focuses on pain control without opioids, which gives it a clear place in the healthcare market. It is not a broad drug maker; it is a specialty company built around a few branded products that are meant to be used in specific procedures and treatment settings.
Pacira Biosciences makes non-opioid pain relief products for hospitals, surgery centers, and doctors. Its main product is EXPAREL, a long-acting injectable used to control pain after surgery. It also sells ZILRETTA for knee osteoarthritis pain and iovera, a device that uses cold to block pain nerves for certain procedures.
The company makes money mainly by selling these prescription products to healthcare providers and through the pharmacy and hospital supply chain. Doctors use Pacira’s medicines and devices when they want to reduce opioid use, manage pain for a longer period, or improve recovery after surgery or joint treatment.
Pacira stands out because it focuses on pain control without opioids, which gives it a clear place in the healthcare market. It is not a broad drug maker; it is a specialty company built around a few branded products that are meant to be used in specific procedures and treatment settings.
Results: Pacira said first-quarter results were strong and consistent with the momentum it saw in the second half of 2025, reinforcing confidence in its 5x30 strategy.
EXPAREL: Net sales rose to $143.3 million from $136.5 million a year ago, helped by about 7% volume growth, though revenue was held back by vial mix, discounting from a third GPO, and winter storm disruptions.
Other products: ZILRETTA sales grew 15% to $26.8 million and iovera sales rose 21% to $6.2 million, both benefiting from dedicated sales efforts and expanded commercial reach.
Guidance: Full-year 2026 guidance was reiterated, including total revenue of $745 million to $770 million and EXPAREL sales of $600 million to $620 million.
Pipeline: Management highlighted several near-term catalysts, including top-line data later this year for PCRX-201 and ZILRETTA shoulder OA, plus year-end data for the iovera spasticity study.
Capital: The company ended the quarter with $202 million in cash and investments, bought back $50 million of stock, and said it remains disciplined on capital deployment and partnerships.
